Eiger Biopharmaceuticals (NASDAQ:EIGR) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.92) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.82) by ($0.10), Fidelity Earnings reports.
Shares of EIGR traded up $0.12 during midday trading on Friday, hitting $13.43. The stock had a trading volume of 200 shares, compared to its average volume of 96,659. Eiger Biopharmaceuticals has a fifty-two week low of $8.20 and a fifty-two week high of $18.00. The stock has a market cap of $250.53 million, a price-to-earnings ratio of -2.77 and a beta of 1.48. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.59 and a quick ratio of 4.59.
In other news, Director Thomas John Dietz bought 5,000 shares of the firm’s stock in a transaction on Thursday, December 20th. The stock was bought at an average cost of $9.98 per share, for a total transaction of $49,900.00. Following the completion of the acquisition, the director now directly owns 10,000 shares in the company, valued at approximately $99,800. The purchase was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 7.90% of the company’s stock.
An institutional investor recently raised its position in Eiger Biopharmaceuticals stock. Dimensional Fund Advisors LP grew its position in Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) by 127.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,750 shares of the biotechnology company’s stock after buying an additional 20,625 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.19% of Eiger Biopharmaceuticals worth $373,000 at the end of the most recent quarter. Institutional investors own 81.76% of the company’s stock.
EIGR has been the subject of several research reports. Wedbush restated a “buy” rating and set a $43.00 price objective on shares of Eiger Biopharmaceuticals in a research report on Tuesday, February 19th. BidaskClub lowered shares of Eiger Biopharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 14th. Zacks Investment Research upgraded shares of Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 price objective for the company in a research report on Tuesday, February 5th. ValuEngine upgraded shares of Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, January 15th. Finally, BTIG Research raised their price objective on shares of Eiger Biopharmaceuticals from $44.00 to $47.00 and gave the company a “buy” rating in a research report on Wednesday, December 19th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $31.88.
TRADEMARK VIOLATION NOTICE: This article was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.dispatchtribunal.com/2019/03/15/eiger-biopharmaceuticals-eigr-posts-quarterly-earnings-results-misses-estimates-by-0-10-eps.html.
Eiger Biopharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.
Featured Article: Google Finance Portfolio
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.